Response to pioglitazone in non-alcoholic fatty liver disease patients with
diabetes mellitus
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
pioglitazone
randomized controlled trials
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
11
2022
accepted:
13
02
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD). However, different effects of pioglitazone on NAFLD have been demonstrated in diabetic and non-diabetic patients. Herein, a meta-analysis of randomized, placebo-controlled trials was carried out to indirectly compare pioglitazone in NAFLD patients with Randomized controlled trials (RCTs) of pioglitazone The review covered seven articles, with 614 patients in total, of which three were non-diabetic RCTs. No difference was found in patients with Pioglitazone could exert a certain effect on alleviating NAFLD, which was consistent between non-diabetic NAFLD patients and diabetic NAFLD patients in improving histopathology, liver enzymes, and HOMA-IR and reducing blood lipids. Furthermore, there were no adverse effects, except the incidence of edema which is higher in the pioglitazone group in NAFLD patients with diabetes. However, large sample sizes and well-designed RCTs are required to further confirm these conclusions.
Sections du résumé
Background
Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD). However, different effects of pioglitazone on NAFLD have been demonstrated in diabetic and non-diabetic patients. Herein, a meta-analysis of randomized, placebo-controlled trials was carried out to indirectly compare pioglitazone in NAFLD patients with
Methods
Randomized controlled trials (RCTs) of pioglitazone
Results
The review covered seven articles, with 614 patients in total, of which three were non-diabetic RCTs. No difference was found in patients with
Conclusions
Pioglitazone could exert a certain effect on alleviating NAFLD, which was consistent between non-diabetic NAFLD patients and diabetic NAFLD patients in improving histopathology, liver enzymes, and HOMA-IR and reducing blood lipids. Furthermore, there were no adverse effects, except the incidence of edema which is higher in the pioglitazone group in NAFLD patients with diabetes. However, large sample sizes and well-designed RCTs are required to further confirm these conclusions.
Identifiants
pubmed: 37065735
doi: 10.3389/fendo.2023.1111430
pmc: PMC10091905
doi:
Substances chimiques
Pioglitazone
X4OV71U42S
Hypoglycemic Agents
0
Lipids
0
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111430Informations de copyright
Copyright © 2023 Wang, Du, Zhao, Ren, Ma, Chen, Li, Tian, Xue, Long, Xu and Jiang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Drugs. 2010 Oct 22;70(15):1945-61
pubmed: 20883052
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Hepatol. 2011 Dec;55(6):1383-90
pubmed: 21703200
J Hepatol. 2007 Oct;47(4):565-70
pubmed: 17560678
Front Endocrinol (Lausanne). 2021 Apr 28;12:615409
pubmed: 33995271
Diabetes Care. 2019 Aug;42(8):1481-1488
pubmed: 31332029
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
PLoS One. 2015 Aug 07;10(8):e0134172
pubmed: 26252777
Hepatol Int. 2021 Oct;15(5):1136-1147
pubmed: 34386935
J Gastroenterol. 2021 Nov;56(11):951-963
pubmed: 34533632
Endocr Pract. 2003 Sep-Oct;9(5):406-16
pubmed: 14583425
N Engl J Med. 2016 Aug 18;375(7):704
pubmed: 27532845
J Clin Endocrinol Metab. 2006 Sep;91(9):3418-25
pubmed: 16804048
JAMA Intern Med. 2017 May 1;177(5):633-640
pubmed: 28241279
Hepat Mon. 2012 Aug;12(8):e6099
pubmed: 23087748
Liver Int. 2018 Feb;38 Suppl 1:52-55
pubmed: 29427486
Cureus. 2021 Oct 25;13(10):e19046
pubmed: 34858740
Clin Gastroenterol Hepatol. 2018 Apr;16(4):558-566.e2
pubmed: 29223443
Cancer Med. 2018 Apr;7(4):1070-1080
pubmed: 29476615
Hepatology. 2012 Oct;56(4):1311-8
pubmed: 22532269
Am J Physiol Gastrointest Liver Physiol. 2016 Apr 1;310(7):G526-38
pubmed: 26797396
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166
pubmed: 17253544
Diabetes Obes Metab. 2023 Apr;25(4):1112-1116
pubmed: 36495442
Aliment Pharmacol Ther. 2015 Feb;41(3):301-9
pubmed: 25429853
Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1385-1388
pubmed: 29023319
JAMA. 2020 Mar 24;323(12):1175-1183
pubmed: 32207804
Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15
pubmed: 15625656
Hepatology. 2014 Jun;59(6):2188-95
pubmed: 24375711
Diabetes Ther. 2021 Mar;12(3):843-861
pubmed: 33586120
Ann Intern Med. 2016 Sep 6;165(5):305-15
pubmed: 27322798
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Aliment Pharmacol Ther. 2012 Jan;35(1):66-75
pubmed: 22050199
J Gastroenterol Hepatol. 2021 Jan;36(1):249-256
pubmed: 32506513
Diabet Med. 2013 Sep;30(9):1026-32
pubmed: 23350856
Eur J Gastroenterol Hepatol. 2019 May;31(5):613-617
pubmed: 30920975
N Engl J Med. 2006 Nov 30;355(22):2297-307
pubmed: 17135584
BMC Cardiovasc Disord. 2014 Sep 26;14:129
pubmed: 25260374
Front Endocrinol (Lausanne). 2021 Oct 14;12:735824
pubmed: 34721294
Biol Sex Differ. 2021 Jan 4;12(1):1
pubmed: 33397443
Ann Hepatol. 2017 Aug 1;16(4):538-547
pubmed: 28611274
N Engl J Med. 2010 May 6;362(18):1675-85
pubmed: 20427778
Hepatology. 2009 Oct;50(4):1087-93
pubmed: 19670459
Am J Gastroenterol. 2017 Apr;112(4):581-587
pubmed: 28195177
Diabetes Res Clin Pract. 2018 Jan;135:102-110
pubmed: 29146119
Biochim Biophys Acta. 2012 May;1821(5):809-18
pubmed: 22056763
J Diabetes. 2019 Mar;11(3):223-231
pubmed: 30073778
Hepatology. 2019 Aug;70(2):522-531
pubmed: 30549292
Aliment Pharmacol Ther. 2010 Nov;32(10):1211-21
pubmed: 20955440
Intern Med J. 2020 Sep;50(9):1038-1047
pubmed: 31760676
J Clin Exp Hepatol. 2012 Dec;2(4):333-7
pubmed: 25755455
Aliment Pharmacol Ther. 2010 Sep;32(6):769-75
pubmed: 20662773
Diabetes Res Clin Pract. 2021 Aug;178:108984
pubmed: 34311022
Gastroenterology. 2008 Oct;135(4):1176-84
pubmed: 18718471
Liver Int. 2021 Nov;41(11):2659-2670
pubmed: 34219361
J Clin Epidemiol. 1992 Jul;45(7):769-73
pubmed: 1619456
Contemp Clin Trials. 2009 Jan;30(1):88-96
pubmed: 18804555
Medicine (Baltimore). 2016 Oct;95(42):e4947
pubmed: 27759627
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Cells. 2019 Dec 21;9(1):
pubmed: 31877771
BMJ. 2016 Aug 16;354:i3903
pubmed: 27530399